The FDA has directed manufacturers to remove B/Yamagata from influenza vaccines

CSL Seqirus is prepared for this change and will be bringing our full portfolio of influenza vaccines to the US market as trivalent formulations for the 2024-2025 season.
Everything you need to simplify your vaccination business
flu360® partners you with true flu professionals and solutions. Create an account to get started.
flu360 Solutions
Built to help your clinic or network overcome challenges both unique and common.
Clinical Support
Discover influenza vaccine technologies, access vaccine expertise, and download clinic tools and resources.
Financial Guidance
Understand financial status, and manage invoices and payment methods.
Operational Efficiency
Place and track orders while managing inventory and overall performance.
We're here to strengthen and support your flu vaccination efforts
CSL Seqirus understands the complexities of managing flu vaccinations. When you sign up with flu360, you gain a dedicated partner, expert vaccination support and service, and access to CSL Seqirus' differentiated flu vaccine portfolio.
Explore the CSL Seqirus Vaccine Portfolio
Please see Important Safety Information and full US Prescribing Information on each vaccine's respective product page.
Access Featured Resources
FLUAD QUADRIVALENT | CLINICAL
FLUAD® QUADRIVALENT ACIP Recommendation Flyer
Review a summary of the ACIP decision to preferentially recommend FLUAD QUADRIVALENT as seasonal influenza vaccine for adults 65+.
CLINICAL
Flu Clinic Resource Toolkit
Raise flu vaccination awareness among your patients with downloadable materials.
FINANCIAL
CSL Seqirus Portfolio Coding and Billing Guide
Access the latest coding and billing info for CSL Seqirus flu vaccines all in one place.
Brought to you by CSL Seqirus
As a leading flu vaccine manufacturer and your partner in public health, CSL Seqirus is committed to working with you to grow your immunization clinic business through flu360.